CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0035 (clinicaltrials.gov NCT No: NCT01321008)
Title:Radiation Therapy Followed by Chemotherapy for Newly Diagnosed Patients with Stage I/II Nasal NK Cell Lymphoma
Principal Investigator:Bouthaina Dabaja
Treatment Agent:Adriamycin; Cyclophosphamide; Prednisone; Radiation; Vincristine
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if radiation therapy and
chemotherapy can help control stage 1 and/or 2 NK cell lymphoma. The safety of
radiation and chemotherapy will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:Adriamycin
Cyclophosphamide
Prednisone
Radiation
Vincristine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Bouthaina Dabaja
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2300
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults